市場調查報告書

血漿分餾的全球市場:未來展望

Global Plasma Fractionation Market - 2019-2026

出版商 DataM Intelligence 商品編碼 908335
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
血漿分餾的全球市場:未來展望 Global Plasma Fractionation Market - 2019-2026
出版日期: 2020年01月01日內容資訊: 英文
簡介

本報告提供全球血漿分餾製劑的市場相關分析,市場基本結構及最新形勢,整體市場趨勢預測 (今後8年份),各產品、各用途、各終端用戶及各地區詳細趨勢,主要的推動及阻礙市場要素,市場競爭結構,主要企業的簡介、事業策略等相關調查。

第1章 全球血漿分餾市場:分析方法、範圍

第2章 全球血漿分餾市場:市場定義和概要

第3章 全球血漿分餾市場:摘要整理

第4章 全球血漿分餾市場:市場動態

  • 對市場的影響要素
    • 推動市場要素
    • 阻礙市場要素
    • 市場機會
    • 影響度分析

第5章 全球血漿分餾市場:產業分析

  • 波特的五力分析
  • 法規分析
  • 供應鏈分析
  • 價格趨勢分析
  • 未滿足需求

第6章 全球血漿分餾市場:各產品

  • 簡介
  • 市場規模、年度成長率分析:各產品
  • 市場向心力指標:各產品
    • 白蛋白
      • 概要
      • 市場規模、年度成長率 (以金額為準,今後9年份)
    • 免疫球蛋白
      • 皮下注射用免疫球蛋白 (SCIG)
      • 靜脈注射用免疫球蛋白 (IVIG)
    • 凝血因子製劑
      • 馮威里氏因子 (Von Willebrand Factor)
      • 第九凝血因子
      • 第八凝血因子
      • 凝血因子XIII
      • 纖維蛋白原濃縮製劑
      • 凝血酵素原複合物濃縮劑
    • 蛋白分解酵素阻礙要素
    • 其他

第7章 全球血漿分餾市場:各用途

  • 簡介
  • 市場規模、年度成長率分析:各用途
  • 市場向心力指標:各用途
    • 免疫疾病
      • 簡介
      • 市場規模、年度成長率 (以金額為準,今後9年份)
    • 神經症
    • 血液腫瘤
    • 血液疾病
    • 重症加護
    • 肺部疾病
    • 風濕
    • 其他

第8章 全球血漿分餾市場:各終端用戶

  • 簡介
  • 市場規模、年度成長率分析:各終端用戶
  • 市場向心力指標:各終端用戶
    • 臨床檢驗室
      • 簡介
      • 市場規模、年度成長率 (以金額為準,今後9年份)
    • 醫院、診所
    • 教育機關
    • 其他

第9章 全球血漿分餾市場:各地區

  • 簡介
    • 市場規模、年度成長率分析:各地區
    • 市場向心力指標:各地區
  • 北美 (美國,加拿大,墨西哥)
    • 簡介
    • 市場規模、年度成長率:各產品 (以金額為準,今後9年份)
    • 市場規模、年度成長率:各用途 (以金額為準,今後9年份)
    • 市場規模、年度成長率:各終端用戶 (以金額為準,今後9年份)
    • 市場規模、年度成長率:各國 (以金額為準,今後9年份)
  • 歐洲 (德國,英國,法國,義大利,西班牙等)
  • 南美 (巴西,阿根廷等)
  • 亞太地區 (中國,印度,日本,澳洲等)
  • 中東、非洲

第10章 全球血漿分餾市場:競爭環境

  • 競爭方案
  • 市場定位/佔有率分析
  • 企業合併、收購 (M&A)的分析

第11章 企業簡介

  • CSL
    • 企業概要
    • 產品系列/概要
    • 近幾年的主要趨勢
    • 財務分析:概要
  • Grifols
  • China Biologic Products
  • Shire (武田藥品工業)
  • Octapharma Plasma, Inc.
  • Kedrion S.p.A
  • Sanquin
  • LFB SA

第12章 全球血漿分餾市場:重要考察

第13章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Plasma Fractionation Market Overview

Plasma fractionation is a method of separating various components of blood plasma to treat protein deficiency in individuals and also in industrial applications as packaging material. It is used in prevention and treatment of life threatening diseases caused by trauma, immunologic disorders, and infections. The global Plasma Fractionation market size was worth $ XX billion in 2018 and is forecasted to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period (2019-2026).

Plasma Fractionation Market Dynamics

The rising prevalence of respiratory diseases and alpha-1 antitrypsin deficiency (ATTD) along with growing geriatric population, increasing use of immunoglobulins in various therapeutic applications are some of the factors driving the growth of the plasma fractionation market.

Alpha-1 Antitrypsin (AAT) is a protein made in the liver in healthy humans, and certain genetic defects diminish or eliminate the liver's ability to make AAT. An AAT deficiency causes a variety of conditions, including emphysema, neonatal hepatitis, jaundice, and chronic obstructive pulmonary disease (COPD). Alpha1-antitrypsin deficiency (AATD) is one of the most common genetic disorders associated with significant morbidity and mortality. The prevalence of diagnosed AATD increases with age. According to the European Respiratory Journal, 2017, it is estimated that the number of diagnosed AATD patients in Germany was 19 162, of whom an estimated 8684 patients would have had an additional pulmonary diagnosis. The prevalence of COPD and emphysema in AATD was 32% and 21%, respectively. In addition, according to the WHO, Respiratory diseases are leading causes of death and disability in the world. About 65 million people suffer from chronic obstructive pulmonary disease (COPD) and 3 million die from it each year, making it the third leading cause of death worldwide. About 334 million people suffer from asthma, the most common chronic disease of childhood affecting 14% of all children globally. Hence, the rising prevalence of various respiratory diseases and Alpha1-antitrypsin deficiency (AATD) is driving the growth of the plasma fractionation market globally.

Various advancements in the product by major manufacturers is also one of the major factor contributing to the growth of the market. For instance, in June 2019, Grifols, launched the VISTASEAL™ fibrin sealant with Ethicon Inc. as part of a broad global relationship to provide plasma-protein-based solutions to manage surgical bleeding. Also, in September 2018, Grifols launched GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis, and Prolastin-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency.

However, the high cost of plasma products, the emergence of recombinant alternatives, and limited reimbursements are some of the factors hindering the growth of the plasma fractionation market during the forecast period.

Plasma Fractionation Market Segment Analysis

By product, the plasma fractionation market is segmented into albumin, immunoglobulins, coagulation factor concentrates, protease inhibitors, and others. Among these, the immunoglobulin segment accounted for the largest market share in 2018 and expected to dominate the plasma fractionation market during the forecast period (2019-2026). The immunoglobulins segment is further classified into subcutaneous immunoglobulins, intravenous immunoglobulins, and others. The intravenous immunoglobulins (IVIg) held the largest market share in 2018 as it is the most extensively used plasma product globally for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis, dermatomyositis, hypogammaglobinemia, Guillain-Barre syndrome, immune cytopenias, primary antibody deficiency, vacuities, asthma, and systemic lupus erythematosus, among other disorders. The rising prevalence of these disorders is fuelling the growth of this segment. The subcutaneous immunoglobulins (SCIg) segment is estimated to grow at the highest CAGR during the forecast period (2019-2026). SCIg has several advantages over IVIg such as; it is the best alternative for patients with limited vascular access who cannot tolerate adverse effects associated with IVIg. Slow administration and absorption of SCIg reduce the rapid variation in serum Ig levels, which further reduces adverse drug reactions. These advantages are expected to drive the growth in this product segment. The major players are innovating new products which lead to the growth of the immunoglobulins market. For instance, in September 2018, Grifols launched GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis, and Prolastin-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency.

The coagulation factor market is segmented into Von Willebrand Factor, Factor IX, Factor VIII, Factor XIII, Fibrinogen Concentrates, and Prothrombin Complex. Among these, the concentrate Factor VIII segment held the highest share in the coagulation factor concentrates market, owing to the rising geriatric population, rising number of hemophilic patients, increasing preference for prophylactic treatments for people suffering from hemophilia, and increasing diagnosis of hemophilia. In addition, the unavailability of advanced therapies in developing countries for a majority of hemophilia patients is also expected to drive the growth of this segment.

Plasma Fractionation Market Geographical Analysis

North America holds the dominant market share for plasma fractionation in 2018, and it is expected to maintain the growth over the forecast period, owing to increasing use of immunoglobulins in various applications such as neurological and autoimmune diseases. The growing number of respiratory diseases will increase the adoption of coagulation factors, which in turn will drive the market for plasma fractionation in North America. The burden of respiratory diseases is increasing in United States. According to the National Center for Health Statistics, currently more than 25 million people in the United States have asthma and approximately 14.8 million adults have been diagnosed with COPD. COPD is the 4th leading cause of death in the United States. According to the Centers for Disease Control and Prevention (CDC), in 2014, approximately 142,000 individuals died from COPD, and almost as many died from lung cancer (approximately 155,500) in the same year. In nearly 8 out of 10 cases, COPD is caused by exposure to cigarette smoke. Other environmental exposures (such as those in the workplace) may also cause COPD.

There are advancements in processes, improved formulations, and increased production efficiency. Advancement in technology leads to improved process of plasma manufacturing, hence leading to growth of the market in this region. There are many clinics across the region for targeted gene therapies with new advancements in treatments related to cardiovascular diseases, cancer immunotherapies, and blood-related disorders. Several innovations in manufacturing processes (e.g. improvement of yield), product developments (e.g. such as subcutaneous IG, IVIg 10% concentration, and IVIg liquid presentation), presence of advanced virus removal technologies (such as nanofiltration), and the development of newer plasma products such as ceruloplasmin and IgA are also supporting the growth of the plasma fractionation market in these regions. For instance, in August 2016, Shire, announced the U.S. launch of VONVENDI [von Willebrand factor (Recombinant)], the only recombinant treatment for adults living with von Willebrand disease (VWD). The treatment is also the first in the United States that has the option to dose recombinant von Willebrand factor (rVWF) independent of recombinant Factor VIII (rFVIII), based on patient need. This attribute allows for tailored treatment for patients who may not require additional FVIII.

Plasma Fractionation Market Competitive Landscape

The Plasma Fractionation market is dominated by few major players including CSL, Grifols, China Biologic Products, Shire (Takeda Pharmaceutical Company), Octapharma Plasma, Inc., Kedrion S.p.A, Sanquin, and LFB SA. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the Plasma Fractionation market globally. For instance,

In June 2019, Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, launched the VISTASEAL™ fibrin sealant with Ethicon Inc. as part of a broad global relationship to provide plasma-protein-based solutions to manage surgical bleeding.

In March 2019, Grifols acquired $1.9 billion stake in Shanghai RAAS Blood Products Co., gaining a major foothold in China's booming blood-products market.

In January 2019, Takeda Pharmaceutical Company Limited (Japan), a global biopharmaceutical company acquired Shire, increasing its geographic footprint and global customer base.

In September 2018, Grifols launched GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis, and Prolastin-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency.

In September 2018, Octapharma invested USD 25 million (Euro 21 million) in a new multi-function facility in Springe, Germany, that will have a new production line for human normal immunoglobulin panzyga, alongside with human albumi and albunorm.

In August 2018, Grifols acquired Biotest US Corporation, a subsidiary of Biotest (Germany), to expand its plasma collection network with the addition of 24 Biotest centers in the US.

In February 2018, Guizhou Taibang Biological Products Co. Ltd., a wholly-owned subsidiary of China Biologic Products Organization, received approval from the Hainan Provincial Health and Family Planning Commission to build a new plasma collection station in Hainan Province.

Why Purchase the Report?

  • Visualize the composition of the plasma fractionation products in various applications highlighting the key commercial assets and players.
  • Identify commercial opportunities in plasma fractionation market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of plasma fractionation market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Plasma Fractionation Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Plasma Fractionation Market - Market Definition and Overview

3. Global Plasma Fractionation Market - Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by End-User

4. Global Plasma Fractionation Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Respiratory Diseases
      • 4.1.1.2. Growing aging population globally
      • 4.1.1.3. Increasing demand of Immunoglobulins in various Therapeutic Areas
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Government Regulations
      • 4.1.2.2. High Cost and Limited Reimbursement
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Plasma Fractionation Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. Global Plasma Fractionation Market - By Product

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
  • 6.3. Market Attractiveness Index, By Product Segment
    • 6.3.1. Albumin*
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    • 6.3.2. Immunoglobulins
      • 6.3.2.1. Subcutaneous Immunoglobulins
      • 6.3.2.2. Intravenous Immunoglobulins
      • 6.3.2.3. Others
    • 6.3.3. Coagulation Factor Concentrates
      • 6.3.3.1. Von Willebrand Factor
      • 6.3.3.2. Factor IX
      • 6.3.3.3. Factor VIII
      • 6.3.3.4. Factor XIII
      • 6.3.3.5. Fibrinogen Concentrates
      • 6.3.3.6. Prothrombin Complex Concentrate
    • 6.3.4. Protease Inhibitors
    • 6.3.5. Others

7. Global Plasma Fractionation Market - By Application

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 7.3. Market Attractiveness Index, By Application Segment
    • 7.3.1. Immunology*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    • 7.3.2. Neurology
    • 7.3.3. Hemato-Oncology
    • 7.3.4. Hematology
    • 7.3.5. Critical Care
    • 7.3.6. Pulmonology
    • 7.3.7. Rheumatology
    • 7.3.8. Others

8. Global Plasma Fractionation Market - By End-User

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
  • 8.3. Market Attractiveness Index, By End-User Segment
    • 8.3.1. Clinical Research Laboratories*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    • 8.3.2. Hospitals & Clinics
    • 8.3.3. Academic Institutes
    • 8.3.4. Others

9. Global Plasma Fractionation Market - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

10. Global Plasma Fractionation Market - Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. CSL*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Grifols
  • 11.3. China Biologic Products
  • 11.4. Shire (Takeda Pharmaceutical Company)
  • 11.5. Octapharma Plasma, Inc.
  • 11.6. Kedrion S.p.A
  • 11.7. Sanquin
  • 11.8. LFB SA

12. Global Plasma Fractionation Market - Premium Insights

13. Global Plasma Fractionation Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us